Home computer-based brain training for mild cognitive impairment or subjective cognitive decline
Tests RICORDO home brain training against an education program in older adults with memory concerns.
Key facts
- Who runs it
- Giovanna Zamboni
- Where
- Italy2 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Personalized Digital Training for COGnitive FITness in Mild Cognitive Impairment
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 28 Nov 2025
- Expected to end
- 30 Nov 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- RICORDO
- S.A.M.B.A.
- Record updated
- 29 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 50 or older with Mild Cognitive Impairment (MCI) or Subjective Cognitive Decline (SCD). They will do a 5-week home program, either digital brain training with RICORDO or an education program.
- Age
- 50 years or older
- Sex
- All sexes
- Disease stage
- Mild Cognitive Impairment (MCI) or Subjective Cognitive Decline (SCD). MMSE score above 18 and CDR score of 1 or less.
- Earlier treatment
- Any medicine acting on the brain must have been stable for the past 3 months. People who took part in a cognitive or rehabilitation program in the last 3 months cannot join.
Main reasons for not taking part
- Severe problems with senses or communication
- Other brain disorders that may affect thinking, such as major stroke, brain tumor or brain injury
- Major psychiatric disorders
- Medical conditions that may affect thinking, such as kidney or liver failure, sleep apnea, low thyroid or vitamin B12 deficiency
- Under legal guardianship, unable to understand and use written and spoken Italian, or 3 years of schooling or less
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Diagnosis of Mild Cognitive Impairment (MCI) based on Petersen (1999) and Winblad (2004), or Subjective Cognitive Decline (SCD) according to Jessen (2014)
- Mini-Mental State Examination (MMSE) > 18 and Clinical Dementia Rating (CDR) ≤ 1
- Age ≥ 50 years
- Formal education > 3 years
- Signed informed consent
- Stable neurotropic pharmacological therapy in the past 3 months (if applicable)
- Preserved mental capacity (i.e., not under legal guardianship or protective supervision)
- Preserved ability to understand and produce written and spoken Italian
Who cannot take part
- Failure to provide or withdrawal of informed consent
- History or evidence of central nervous system disorders that may affect cognition and are unrelated to the study (e.g., major stroke, brain tumors, normal pressure hydrocephalus, traumatic brain injury)
- History or evidence of major psychiatric disorders
- Presence of medical conditions that may interfere with cognitive function (e.g., renal or hepatic failure, obstructive sleep apnea, hypothyroidism, vitamin B12 deficiency)
- Severe sensory or communication impairments
- Recent participation (< 3 months) in cognitive or rehabilitation programs
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to determine whether a home-based digital cognitive-training program called RICORDO can enhance patients' ability to manage their own health and daily life when they have Mild Cognitive Impairment (MCI) or Subjective Cognitive Decline (SCD) and are 50 years of age or older.
Read full original descriptionShow less
The main questions it aims to answer are:
Does using RICORDO for five weeks raise the Patient Activation Measure (PAM) score more than an at-home paper-and-video education program called S.A.M.B.A.?
Does RICORDO also improve cognition, everyday functioning, quality of life and mood compared with S.A.M.B.A.?
Researchers will compare individuals who train with RICORDO to those who follow S.A.M.B.A. to determine which approach is more effective.
Participants will be randomly assigned to one of the two groups and complete three 45-minute sessions per week at home for five weeks. They will also visit the clinic at the beginning and end of the program to complete questionnaires and take brief thinking tests.
The 2 groups in the trial
- RICORDO - Digital Cognitive RehabilitationTreatment being tested
Participants assigned to this arm will receive a 5-week personalized cognitive training program using the CE-marked digital therapeutic RICORDO. The intervention consists of 15 tablet-based home sessions (3 per week, 45 minutes each), tailored to the participant's cognitive profile and performance, and remotely monitored by clinicians via a web platform.
Treatment: RICORDO
- S.A.M.B.A. - Lifestyle Education ProgramExisting treatment, for comparison
Participants assigned to this arm will follow a 5-week home-based educational program called S.A.M.B.A., which includes 15 sessions (3 per week) using printed and video materials focused on socialization, healthy nutrition, physical activity, psychological well-being, and environmental stimulation. This arm is matched for contact time and format but does not include cognitive training.
Treatment: S.A.M.B.A.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Personalized Digital Training for COGnitive FITness in Mild Cognitive Impairment: the COG-FIT Pragmatic Trial
- Plain-language title
- Home computer-based brain training for mild cognitive impairment or subjective cognitive declineGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 29 April 2026